INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients

Core Insights - INmune Bio Inc. presented significant findings on the effects of XPro™ on synaptic proteins and pathways at the Alzheimer's Association International Conference (AAIC) [1][2] - The analysis showed that a 12-week treatment with XPro™ led to notable changes in synaptic proteins crucial for neuron communication [2][3] - The company is currently conducting a phase 2 clinical trial for mild to moderate Alzheimer's patients, with top-line results expected in early 2025 [4] Company Overview - INmune Bio Inc. is a clinical-stage company focused on inflammation and immunology, developing treatments that leverage the innate immune system [1][6] - The company has two main product platforms in clinical trials: the Dominant-Negative Tumor Necrosis Factor (DNTNF) platform and the Natural Killer Cell Priming Platform [6] - XPro™ is a next-generation TNF inhibitor that neutralizes soluble TNF without affecting trans-membrane TNF or TNF receptors, potentially reducing neuroinflammation without immunosuppression [5][6] Research Findings - The loss of synapses in Alzheimer's disease has severe consequences, and XPro™ has shown a robust effect on proteins and pathways that regulate synapse formation [3][4] - The treatment's impact on synaptic proteins aligns with previous observations in preclinical models, suggesting a restoration of normal immune function [3][4] - The company believes that the biological effects observed may lead to cognitive benefits, which are currently being tested in ongoing trials [4]